<SEC-DOCUMENT>0001206774-16-007185.txt : 20160912
<SEC-HEADER>0001206774-16-007185.hdr.sgml : 20160912
<ACCEPTANCE-DATETIME>20160912074527
ACCESSION NUMBER:		0001206774-16-007185
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20160912
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20160912
DATE AS OF CHANGE:		20160912

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GERON CORP
		CENTRAL INDEX KEY:			0000886744
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				752287752
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-20859
		FILM NUMBER:		161880036

	BUSINESS ADDRESS:	
		STREET 1:		149 COMMONWEALTH DRIVE
		STREET 2:		SUITE 2070
		CITY:			MENLO PARK
		STATE:			CA
		ZIP:			94025
		BUSINESS PHONE:		6504737700

	MAIL ADDRESS:	
		STREET 1:		149 COMMONWEALTH DRIVE
		STREET 2:		SUITE 2070
		CITY:			MENLO PARK
		STATE:			CA
		ZIP:			94025

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GERON CORPORATION
		DATE OF NAME CHANGE:	19960521
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>geron3126131-8k.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>

<HTML>
<HEAD>
   <TITLE></TITLE>
</HEAD>

<BODY bgcolor=#ffffff>
<BR>
<P align=center><B><FONT face="Times New Roman" size=2>UNITED
STATES<BR></FONT></B><B><FONT face="Times New Roman" size=2>SECURITIES AND
EXCHANGE COMMISSION<BR>WASHINGTON, D.C. 20549 <BR>___________<BR></FONT></B></P>
<P align=center><B><FONT face="Times New Roman" size=2>FORM 8-K </FONT></B></P>
<P align=center><B><FONT face="Times New Roman" size=2>CURRENT
REPORT<BR></FONT></B><B><FONT face="Times New Roman" size=2>PURSUANT TO SECTION
13 OR 15(d) OF THE<BR>SECURITIES EXCHANGE ACT OF 1934</FONT></B><FONT face="Times New Roman" size=2> </FONT></P>
<P align=center><FONT face="Times New Roman" size=2>Date of Report (Date of
earliest event reported): </FONT><B><FONT face="Times New Roman" size=2>September 12, 2016</FONT></B><FONT face="Times New Roman" size=2>
</FONT></P>
<P align=center><B><FONT face="Times New Roman" size=2>GERON
CORPORATION<BR></FONT></B><FONT face="Times New Roman" size=2>(Exact name of
registrant as specified in its charter)<BR></FONT><B><FONT face="Times New Roman" size=2>___________ </FONT></B></P>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap style="text-align: center" width="32%"><B><FONT face="Times New Roman" size=2>Delaware</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD noWrap style="text-align: center" width="33%"><B><FONT face="Times New Roman" size=2>0-20859</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD noWrap style="text-align: center" width="32%"><B><FONT face="Times New Roman" size=2>75-2287752</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap style="text-align: center" width="32%"><FONT face="Times New Roman" size=2>(State or
      other jurisdiction</FONT></TD>
    <TD noWrap style="text-align: center" width="1%">&nbsp;</TD>
    <TD noWrap style="text-align: center" width="33%"><FONT face="Times New Roman" size=2>(Commission
      File Number)</FONT></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="32%"><FONT face="Times New Roman" size=2>(IRS
      Employer</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap style="text-align: center" width="32%"><FONT face="Times New Roman" size=2>of
      incorporation)</FONT></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="33%"></TD>
    <TD noWrap style="text-align: center" width="1%">&nbsp;</TD>
    <TD noWrap style="text-align: center" width="32%"><FONT face="Times New Roman" size=2>Identification
No.)</FONT></TD></TR></TABLE><BR>
<P align=center><B><FONT face="Times New Roman" size=2>149 COMMONWEALTH DRIVE,
SUITE 2070<BR>MENLO PARK, CALIFORNIA 94025<BR></FONT></B><FONT face="Times New Roman" size=2>(Address of principal executive offices, including
zip code) </FONT></P>
<P align=center><B><FONT face="Times New Roman" size=2>(650)
473-7700<BR></FONT></B><FONT face="Times New Roman" size=2>(Registrant&#146;s
telephone number, including area code) </FONT></P>
<P align=center><B><FONT face="Times New Roman" size=2>N/A<BR></FONT></B><FONT face="Times New Roman" size=2>(Former name or former address, if changed since
last report) </FONT></P>
<P STYLE="text-align: left"><FONT face="Times New Roman" size=2>Check the appropriate box
below if the Form 8-K filing is intended to simultaneously satisfy the filing
obligation of the registrant under any of the following provisions: </FONT></P>
<TABLE style="LINE-HEIGHT: normal; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD vAlign=top noWrap align=left width="1%"><FONT face="Times New Roman" size=2>&#9744;</FONT></TD>
    <TD vAlign=top align=left width="100%"><FONT face="Times New Roman" size=2>Written communications pursuant to Rule 425
      under the Securities Act (17 CFR 230.425)</FONT></TD></TR>
  <TR>
    <TD vAlign=top noWrap align=left width="1%"><FONT size=2 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD vAlign=top align=left width="100%">&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD vAlign=top noWrap align=left width="1%"><FONT face="Times New Roman" size=2>&#9744;</FONT></TD>
    <TD vAlign=top align=left width="100%"><FONT face="Times New Roman" size=2>Soliciting material pursuant to Rule 14a-12
      under the Exchange Act (17 CFR 240.14a-12)</FONT></TD></TR>
  <TR>
    <TD vAlign=top noWrap align=left width="1%"></TD>
    <TD vAlign=top align=left width="100%"><FONT size=2 face="Times New Roman">&nbsp;&nbsp;</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD vAlign=top noWrap align=left width="1%"><FONT face="Times New Roman" size=2>&#9744;</FONT></TD>
    <TD vAlign=top align=left width="100%"><FONT face="Times New Roman" size=2>Pre-commencement communications pursuant to
      Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD vAlign=top noWrap align=left width="1%"></TD>
    <TD vAlign=top align=left width="100%"><FONT size=2 face="Times New Roman">&nbsp;&nbsp;</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD vAlign=top noWrap align=left width="1%"><FONT face="Times New Roman" size=2>&#9744;</FONT></TD>
    <TD vAlign=top align=left width="100%"><FONT face="Times New Roman" size=2>Pre-commencement communications pursuant to
      Rule 13e-4(c) under the Exchange Act (17 CFR
  240.13e-4(c))</FONT></TD></TR></TABLE><BR>
<HR align=center width="100%" noShade size="2">

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=justify><B><FONT face="Times New Roman" size=2>Item 8.01. Other Events.
</FONT></B></P>
<P STYLE="text-align: left; text-indent: 15pt"><FONT face="Times New Roman" size=2>On September 12, 2016,
Geron Corporation issued a press release entitled &#147;Geron Provides Update on
Imetelstat Trials Being Conducted by Janssen.&#148; A copy of the press release is
attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated
herein by reference.</FONT></P>
<P align=justify><B><FONT face="Times New Roman" size=2>Item 9.01. Financial
Statements and Exhibits. </FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>(d) Exhibits. </FONT></P>
<TABLE style="LINE-HEIGHT: normal; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD STYLE="width: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD NOWRAP STYLE="border-bottom: #000000 1pt solid; vertical-align: top; text-align: left; width: 1%"><STRONG><FONT size=2 face="Times New Roman">Exhibit
      No.</FONT></STRONG></TD>
    <TD NOWRAP STYLE="border-bottom: #000000 1pt solid; vertical-align: top; text-align: left; width: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD NOWRAP STYLE="border-bottom: #000000 1pt solid; vertical-align: top; text-align: left; width: 89%"><STRONG><FONT size=2 face="Times New Roman">Description</FONT></STRONG></TD></TR>
  <TR vAlign=bottom>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: top; text-align: left; background-color: #c0c0c0"><FONT face="Times New Roman" size=2>99.1</FONT></TD>
    <TD NOWRAP STYLE="vertical-align: top; text-align: left; background-color: #c0c0c0"></TD>
    <TD STYLE="vertical-align: top; text-align: left; background-color: #c0c0c0"><FONT face="Times New Roman" size=2>Press release dated September 12, 2016,
      entitled &#147;Geron Provides Update on Imetelstat Trials Being Conducted by
      Janssen.&#148;</FONT></TD></TR></TABLE><BR>
<P align=center><FONT face="Times New Roman" size=2>2 </FONT></P>
<HR align=center width="100%" noShade size="2">

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=center><B><FONT face="Times New Roman" size=2>SIGNATURE </FONT></B></P>
<P STYLE="text-align: left; text-indent: 15pt"><FONT face="Times New Roman" size=2>Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly
authorized. </FONT></P>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="50%"></TD>
    <TD noWrap align=left width="49%" colSpan=2><FONT face="Times New Roman" size=2>GERON
      CORPORATION</FONT></TD></TR>
  <TR>
    <TD width="99%" colSpan=3>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="50%"><FONT face="Times New Roman" size=2>Date:
      September 12, 2016</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>By:</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="48%"><FONT face="Times New Roman" size=2>/s/ Stephen N. Rosenfield</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="50%">&nbsp;</TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>Name:&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD noWrap align=left width="48%"><FONT face="Times New Roman" size=2>Stephen N.
      Rosenfield</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="50%"></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>Title:</FONT></TD>
    <TD noWrap align=left width="48%"><FONT face="Times New Roman" size=2>Executive
      Vice President,</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="50%"></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="48%"><FONT face="Times New Roman" size=2>General
      Counsel and</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="50%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="48%"><FONT face="Times New Roman" size=2>Corporate
      Secretary</FONT></TD></TR></TABLE><BR>
<P align=center><FONT face="Times New Roman" size=2>3 </FONT></P>
<HR align=center width="100%" noShade size="2">

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=center><B><FONT face="Times New Roman" size=2>EXHIBIT
INDEX</FONT></B></P>
<TABLE style="LINE-HEIGHT: normal; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top noWrap align=center width="1%"><B><FONT face="Times New Roman" size=2>Exhibit No.</FONT></B></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top noWrap align=left width="1%">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top noWrap align=left width="98%"><B><FONT face="Times New Roman" size=2>Description</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD vAlign=top noWrap align=center width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>99.1</FONT></TD>
    <TD vAlign=top noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD vAlign=top align=left width="98%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>Press release dated September 12, 2016,
      entitled &#147;Geron Provides Update on Imetelstat Trials Being Conducted by
      Janssen.&#148;</FONT></TD></TR></TABLE><BR>
<HR align=center width="100%" noShade size="2">

</BODY>

</HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>geron3126131-ex991.htm
<DESCRIPTION>PRESS RELEASE DATED SEPTEMBER 12, 2016
<TEXT>

<HTML>
<HEAD>
   <TITLE></TITLE>
</HEAD>

<BODY bgcolor=#ffffff>
<BR>
<P align=right><B><FONT face="Times New Roman" size=2>EXHIBIT
99.1</FONT></B></P>
<P align=center><B><FONT style="FONT-VARIANT: small-caps" face="Times New Roman" size=2>Press Release Dated September 12, 2016</FONT></B></P><IMG src="geron3126131-ex991x1x1.jpg" border=0><BR>
<P align=center><B><FONT face="Times New Roman" size=2>Geron Provides Update on
Imetelstat Trials Being Conducted by Janssen</FONT></B></P>
<P align=center><I><FONT face="Times New Roman" size=2>Conference
Call Scheduled for 8:00 a.m. EDT Today,
September 12</FONT></I></P>
<P align=left><FONT face="Times New Roman" size=2><B>MENLO PARK, Calif.,
September 12, 2016</B> --
Geron Corporation (Nasdaq: GERN)
today provided updates on
the clinical trials
being conducted by Janssen
Research &amp; Development, LLC, of the telomerase inhibitor imetelstat. Planned
internal reviews of initial data from both trials
have been completed by Janssen, and
both trials are continuing in order to evaluate additional and
more mature data.</FONT></P>
<P align=left><I><FONT face="Times New Roman" size=2>IMbark<SUP>TM</SUP></FONT></I></P>
<P align=left><FONT face="Times New Roman" size=2>IMbark<SUP>TM
</SUP>(NCT02426086) was
originally designed as a Phase 2
clinical trial to evaluate two dose levels of imetelstat (either
4.7 mg/kg or 9.4 mg/kg administered every
three weeks) in approximately 200 patients (approximately 100 patients per dosing arm) with Intermediate-2 or High
risk myelofibrosis (MF) who
have relapsed after or are refractory to prior treatment with a JAK
inhibitor. The co-primary efficacy endpoints for
the trial are spleen response rate and symptom response
rate at 24 weeks. To date, over
90 patients have been enrolled in the
trial across both dosing
arms.</FONT></P>
<P align=left><FONT face="Times New Roman" size=2>To inform an
assessment of the appropriate dose
and schedule for relapsed or refractory MF patients in
IMbark<SUP>TM</SUP>, Janssen
conducted a planned internal interim
review of safety, efficacy and pharmacokinetic
data from 20 patients from
each dosing arm who have been followed on the trial for
at least 12 weeks. Based on this first internal
review at the early 12-week time point, the following has
been determined by Janssen:</FONT></P>
<TABLE style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse; TEXT-ALIGN: justify" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">
      <P align=left><FONT face="Times New Roman" size=2>The safety profile was consistent with
      previous imetelstat clinical trials
      in hematologic myeloid malignancies. No new
      safety signals were
      identified.<BR>&nbsp;</FONT></P></TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">
      <P align=left><FONT face="Times New Roman" size=2>Activity in the 4.7
      mg/kg dosing arm does not warrant further investigation
      of that dose and this arm will be closed to
      new patient enrollment. An amendment to the trial
      protocol is planned to allow eligible patients in this
      arm to increase their dose to 9.4 mg/kg per investigator discretion.<BR>&nbsp;</FONT></P></TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">
      <P align=left><FONT face="Times New Roman" size=2>In the 9.4 mg/kg        dosing arm, even though at        the week 12 data
      assessment an        insufficient number of patients met the        protocol defined interim criteria, this        arm
      warrants further investigation        because encouraging        trends in the efficacy data were        observed. Patients
      already enrolled in this arm may        continue to receive imetelstat. New        enrollment in this arm will be suspended
      while the trial continues in order to obtain additional and more mature data that includes a longer        follow-up of
      patients at 24 weeks, consistent with the        co-primary efficacy        endpoints. The number of patients enrolled to
      date        is expected to be sufficient to inform potential future development of this dose.<BR>&nbsp;</FONT></P></TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">
      <P align=left><FONT face="Times New Roman" size=2>Janssen plans to
      conduct an additional internal data review in the second
      quarter of 2017 to include
      a longer follow-up of patients at 24 weeks. Potential
      outcomes of the second internal review at the
      24-week time
      point could include resuming enrollment in the 9.4
      mg/kg dosing
      arm, with or without
      changes to the dosing
      regimen; adding
      a new dosing arm; or
      closing the trial.<BR>&nbsp;</FONT></P></TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">
      <P align=left><FONT face="Times New Roman" size=2>Any protocol
      amendments will be subject to
      review by health authorities around the world.</FONT></P></TD></TR></TABLE><BR>
<HR align=center width="100%" noShade size="2">

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=left><I><FONT face="Times New Roman" size=2>IMerge<SUP>TM</SUP> </FONT></I></P>
<P align=left><FONT face="Times New Roman" size=2>IMerge<SUP>TM  </SUP>(NCT02598661) is a Phase 2/3  clinical
trial evaluating imetelstat in transfusion dependent patients  with Low or Intermediate-1 risk myelodysplastic  syndromes
(MDS) who have relapsed after or are refractory to prior treatment with an erythropoiesis stimulating agent (ESA). The
clinical  trial is in two parts: Part 1 is a Phase 2, open-label, single-arm design in approximately 30 patients and Part 2
is a Phase 3, randomized, double-blind, placebo-controlled design in approximately 170 patients. The primary efficacy  endpoint is the rate of red blood cell transfusion-independence lasting at least 8 weeks. Part 1 of the trial is fully
enrolled.</FONT></P>
<P align=left><FONT face="Times New Roman" size=2>Janssen has conducted an
initial internal review of efficacy, safety and pharmacokinetic data from a
subset of patients from Part 1 of IMerge<SUP>TM
</SUP>and this review indicated that
emerging safety and efficacy in IMerge<SUP>TM </SUP>is consistent with data reported
from the pilot study conducted at Mayo Clinic in MDS patients. IMerge<SUP>TM
</SUP>will continue unmodified at this time.</FONT></P>
<P align=left><FONT face="Times New Roman" size=2>Further assessment of data
from IMerge<SUP>TM </SUP>is expected
to occur in the second quarter of 2017 to include longer follow-up of all patients enrolled in Part 1. A decision
on whether to move forward to Part 2 of IMerge<SUP>TM </SUP>will be based on an assessment of the
benefit/risk profile of imetelstat in these patients. If Janssen decides to
move forward with Part 2, the Phase 3 clinical trial is
expected to be open for patient enrollment in mid-2017.</FONT></P>
<P align=left><FONT face="Times New Roman" size=2>Janssen expects to submit data
from Part 1 of IMerge<SUP>TM </SUP>to
be considered for presentation at a medical conference in the
future.</FONT></P>
<P align=left><B><FONT face="Times New Roman" size=2>Conference
Call</FONT></B></P>
<P align=left><FONT face="Times New Roman" size=2>At 8:00 a.m. EDT on September  12, 2016, Geron&#146;s management will host
a conference call to review  outcomes from the internal data reviews of  IMbark<SUP>TM</SUP> and  IMerge<SUP>TM</SUP>.
Participants can access the conference call live  via telephone by dialing 877-303-9139 (U.S.); 760-536-5195
(international). The passcode is 80522983. A  live audio-only webcast is also available on the company&#146;s  website at
www.geron.com under Events and at http://edge.media-server.com/m/p/edpy9b4b. The audio webcast of the conference call will
be  available for replay approximately one hour following the live  broadcast through October 13, 2016.</FONT></P>
<P align=left><B><FONT face="Times New Roman" size=2>About
Imetelstat</FONT></B></P>
<P align=left><FONT face="Times New Roman" size=2>Imetelstat (GRN163L;
JNJ-63935937) is a potent and specific inhibitor of
telomerase that is administered by intravenous infusion. This
first-in-class compound, discovered by Geron, is a
specially designed and modified short oligonucleotide, which targets
and binds directly with high affinity to the active site of telomerase.
Preliminary clinical data suggest imetelstat has
disease-modifying activity by inhibiting the progenitor
cells of the malignant clones associated with hematologic malignancies in
a relatively select manner. Most commonly reported adverse events
in imetelstat clinical studies include fatigue, gastrointestinal symptoms and
cytopenias. Patients in these studies also experienced
elevated liver enzymes, which resolved to normal or baseline in the majority of
patients followed after imetelstat treatment was withdrawn.
Imetelstat has not been approved for marketing by any regulatory authority.</FONT></P>
<P align=left><B><FONT face="Times New Roman" size=2>About the Collaboration
with Janssen</FONT></B></P>
<P align=left><FONT face="Times New Roman" size=2>On November 13, 2014, Geron  entered into an exclusive worldwide
license and collaboration agreement  with Janssen Biotech, Inc., to develop and  commercialize imetelstat for oncology,
including hematologic myeloid malignancies, and all other human therapeutics uses. Under the terms of  the agreement, Geron
received an upfront payment of $35 million  and is eligible to receive additional payments up to a potential total of $900
million for the achievement of development, regulatory and  commercial milestones, as well as royalties on worldwide
net sales.  All regulatory, development, manufacturing and promotional activities related to  imetelstat are being managed
through a joint governance structure, with  Janssen responsible for these activities.</FONT></P>
<HR align=center width="100%" noShade size="2">

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=left><B><FONT face="Times New Roman" size=2>About
Geron</FONT></B></P>
<P align=left><FONT face="Times New Roman" size=2>Geron is a clinical stage
biopharmaceutical company focused on the collaborative development of a first-in-class telomerase inhibitor,
imetelstat, in hematologic myeloid malignancies. For more information about
Geron, visit www.geron.com.</FONT></P>
<P align=left><B><FONT face="Times New Roman" size=2>Use of
Forward</FONT></B><B><FONT face="Times New Roman" size=2>-</FONT></B><B><FONT face="Times New Roman" size=2>Looking Statements</FONT></B></P>
<P align=left><FONT face="Times New Roman" size=2>Except for the historical  information contained herein, this press release
contains forward-looking statements made pursuant to the &#147;safe harbor&#148; provisions of  the Private Securities
Litigation Reform Act of 1995. Investors are cautioned that statements in this press release regarding: (i) continued
conduct by Janssen of IMbark<SUP>TM </SUP>or IMerge<SUP>TM</SUP>; (ii) Janssen obtaining  additional or more mature data from
IMbark<SUP>TM</SUP> or IMerge<SUP>TM</SUP>; (iii) that the  number of patients enrolled in IMbark<SUP>TM </SUP>to date is
sufficient to inform  potential development of the 9.4 mg/kg dose; (iv) that  Janssen will conduct any additional or further
data reviews in or protocol  amendments for IMbark<SUP>TM</SUP> or IMerge<SUP>TM</SUP>, and the timing of such data reviews
or protocol  amendments; (v) potential outcomes of any data reviews  conducted by Janssen; (vi) any future presentation of
data from current clinical  trials of imetelstat by Janssen; (vii) the safety and efficacy of imetelstat; (viii) the
potential receipt by Geron of additional payments up  to a potential total of $900 million for the achievement of
development, regulatory and commercial milestones, and royalties from sales of  imetelstat; and (ix) other statements that
are not historical facts, constitute  forward-looking statements. These statements  involve risks and uncertainties that can
cause actual results to differ  materially from those in such forward-looking statements. These risks and uncertainties,
include, without  limitation, risks and uncertainties related to: (i) whether imetelstat  will succeed in IMbark<SUP>TM</SUP>
and IMerge<SUP>TM  </SUP>by overcoming all of  the clinical safety and efficacy, technical,  scientific, manufacturing and
regulatory challenges; (ii) whether  health authorities permit  IMbark<SUP>TM</SUP> or IMerge<SUP>TM </SUP>to continue to
proceed under  the existing protocols or any amendments thereto; (iii) Janssen&#146;s  ability to collect additional and more
mature data from current clinical trials  of imetelstat; (iv) whether Janssen continues to conduct IMerge<SUP>TM </SUP>or
IMbark<SUP>TM</SUP>; (v) Geron&#146;s dependence on Janssen for the development, regulatory approval, manufacture and
commercialization of  imetelstat, including the risks that if Janssen were to breach or  terminate the collaboration
agreement or otherwise fail to successfully develop  and commercialize imetelstat and in a timely manner,  or at all, Geron
would not obtain the anticipated financial and other  benefits of the collaboration agreement with Janssen and the clinical
development or commercialization of imetelstat could be delayed or  terminated; and (vi) whether imetelstat is safe and
efficacious, and whether  any future efficacy or safety results may cause the  benefit/risk profile of imetelstat to become
unacceptable. Additional information on the above risks and  uncertainties and additional risks, uncertainties and factors
that could  cause actual results to differ materially from those in the forward-looking statements are
contained in Geron&#146;s periodic reports filed  with the Securities and Exchange Commission under the heading
&#147;Risk Factors,&#148; including Geron&#146;s quarterly report on Form 10-Q  for the quarter ended June 30, 2016. Undue
reliance should not be  placed on forward-looking statements, which speak only as of the  date they are made, and the
facts and assumptions underlying the  forward-looking statements may change. Except as required  by law, Geron
disclaims any obligation to update these forward-looking statements to reflect future information, events or
circumstances.</FONT></P>
<P align=left><B><FONT face="Times New Roman" size=2>CONTACT:</FONT></B></P>
<P align=left><FONT face="Times New Roman" size=2>Anna Krassowska,
Ph.D.<BR>Investor and Media Relations<BR>650-473-7765<BR>investor@geron.com<BR>media@geron.com</FONT></P>
<P align=center><FONT face="Times New Roman" size=2>###</FONT></P>
<HR align=center width="100%" noShade size="2">

</BODY>

</HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>geron3126131-ex991x1x1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 geron3126131-ex991x1x1.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  Q & # 2(  A$! Q$!_\0
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M\'^()_AOK6I:IXE^'$$'Q"\7:WXS\=Z-XPN_#'A>7Q/H7@_2_"&@K<7JPZ_
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D?264)\VOZ@** "BBB@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
